{"id":"cdca-weight-based-dose-tid","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL242200","moleculeType":"Small molecule","molecularWeight":"392.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CDCA is an endogenous bile acid that acts as a ligand for nuclear farnesoid X receptor (FXR) and G-protein coupled receptor TGR5. Activation of FXR suppresses CYP7A1, the rate-limiting enzyme in bile acid synthesis, thereby reducing hepatic bile acid production and accumulation. This mechanism helps alleviate cholestasis and associated pruritus in patients with progressive familial intrahepatic cholestasis (PFIC) and other cholestatic liver diseases.","oneSentence":"CDCA (chenodeoxycholic acid) is a bile acid that activates farnesoid X receptor (FXR) and TGR5 signaling to reduce bile acid synthesis and improve cholestasis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:38.885Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Progressive familial intrahepatic cholestasis (PFIC) type 1"},{"name":"Progressive familial intrahepatic cholestasis (PFIC) type 2"}]},"trialDetails":[{"nctId":"NCT04270682","phase":"PHASE3","title":"Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)","status":"COMPLETED","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2020-01-31","conditions":"CTX","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CDCA Weight-Based Dose TID","genericName":"CDCA Weight-Based Dose TID","companyName":"Mirum Pharmaceuticals, Inc.","companyId":"mirum-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CDCA (chenodeoxycholic acid) is a bile acid that activates farnesoid X receptor (FXR) and TGR5 signaling to reduce bile acid synthesis and improve cholestasis. Used for Progressive familial intrahepatic cholestasis (PFIC) type 1, Progressive familial intrahepatic cholestasis (PFIC) type 2.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}